Some Ebola guidelines questioned

Experts questions questioning calls for suspending certain routine lab tests


Experts are questioning aspects of some of the Ebola guidelines that go beyond current Centers for Disease Control and Prevention (CDC) recommendations, especially those that call for suspending certain routine lab tests, according to an article on Infection Control Today.

A commentary in the journal Transfusion suggests that most individuals with suspected Ebola will have a fever due to another cause, and forgoing such testing may compromise patients' health more than any reduction in the risks to laboratory personnel.

The article says that all laboratory directors must work with infection control and safety experts to evaluate their hospital policies on potentially infectious patients to provide a safe environment.

Read the article.

 

 



December 12, 2014


Topic Area: Safety


Recent Posts

Healthcare Is the New Retail

How site selection strategies are shaping the future of medical real estate.


Bridgeway Behavioral Health Services Launches Campaign to Renovate Health Center

The $2 million capital campaign aims to renovate and expand the outpatient behavioral health center in Elizabeth, New Jersey.


Ground Broken for New North Dakota State Hospital

The 300,000-square-foot facility in Jamestown will provide 140 beds in a modern, trauma-informed care environment.


AI Usage for Healthcare Facilities

People in all industries are finding more use cases for artificial intelligence.


Ground Broken on Pelican Valley Senior Living Modernization Project

It is expected to reach completion in early-mid 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.